Who Can Stop This Fire?

DOI QR Code

Hee Jeong Lee (Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Keimyung University Dongsan Hospital, Keimyung University College of Medicine) ;
In-Cheol Kim (Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Keimyung University Dongsan Hospital, Keimyung University College of Medicine)

Cooper LT Jr. Myocarditis. N Engl J Med 2009;360:1526-38.
Zarifa A, Kim JW, Lopez-Mattei J, Palaskas N, Iliescu C, Kim PY. Cardiac toxicities associated with immune checkpoints inhibitors: mechanisms, manifestations and management. Korean Circ J 2021;51:579-97.
Ching S, Yue CS. Fulminant myocarditis after SARS-CoV-2 mRNA vaccine successfully managed with biventricular Impella support: multimodality imaging follow-up. Korean Circ J 2022;52:797-8.
Ammirati E, Frigerio M, Adler ED, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail 2020;13:e007405.
Nagai T, Inomata T, Kohno T, et al. JCS 2023 guideline on the diagnosis and treatment of myocarditis. Circ J 2023;87:674-754.
Kim KJ, Park JB, Lee SP, Kim HK, Kim YJ. Thalidomide and a dipeptidyl peptidase 4 inhibitor in a rat model of experimental autoimmune myocarditis. Korean Circ J 2023;53:795-810.
Bracamonte-Baran W, Cihakova D. Cardiac autoimmunity: myocarditis. Adv Exp Med Biol 2017;1003:187-221.
Packer M. Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials. Circ Res 2018;122:928-32.
Moudgil R, Yeh ET. Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: cardiomyopathy and beyond. Can J Cardiol 2016;32:863-870.e5.